Neuropeptide Y Reduced Anxiety in Rats by Acting on Y2 Receptors in the Lateral Septum | Research

The takeaway

Infusing the neuropeptide Y fragment NPY(13-36) into the lateral septum brain region reduced anxiety-like behavior in rats, but the effect was test-specific and mediated by Y2 receptors.

Highest Y2 receptor density in brain
The lateral septum contains the highest concentration of NPY Y2 receptors in the brain, and this study shows these receptors mediate context-specific anxiety reduction

What the researchers found

Infusion of the NPY Y2 receptor agonist NPY(13-36) into the lateral septum significantly increased open-arm exploration in the elevated plus-maze test — a classic indicator of reduced anxiety. This anxiolytic effect was blocked by pre-treatment with the selective Y2 receptor antagonist BIIE 0246, confirming that Y2 receptors mediate the effect.

However, the anxiolytic action was test-specific: NPY(13-36) reduced burying behavior in the shock-probe burying test but did not reduce anxiety in all threat-related behavioral measures. The Y2 antagonist blocked the plus-maze effect but not the shock-probe effect, suggesting that the anxiolytic actions of lateral septal NPY(13-36) involve Y2-dependent and Y2-independent mechanisms depending on the type of threat.

Why it matters

Anxiety disorders affect millions of people, and current medications like benzodiazepines and SSRIs have significant limitations. Understanding how neuropeptide Y — a naturally occurring brain peptide — regulates anxiety through specific receptor subtypes and brain regions could lead to more targeted anti-anxiety treatments with fewer side effects. The finding that Y2 receptors modulate specific types of anxiety suggests that peptide-based therapies could be designed to address particular anxiety subtypes.

How the study worked

In Experiment 1, male Long Evans rats received infusions of the NPY Y2 agonist NPY(13-36) directly into the lateral septum and were tested across a battery of anxiety models including the elevated plus-maze, shock-probe burying test, and other defensive behavior paradigms. In Experiment 2, rats were pre-infused with the highly selective Y2 antagonist BIIE 0246 before NPY(13-36) to verify Y2 receptor involvement. Behavioral outcomes included open-arm exploration time, burying duration, and other anxiety-related measures.

What this study cannot tell us

This is an animal study using direct brain injection — a method not applicable to human treatment. The lateral septum infusion targets a very specific brain region, and the results may not reflect what happens with systemic NPY administration. Only male rats were studied, so sex differences in NPY-mediated anxiety regulation were not assessed. The different behavioral tests used may involve different forms of anxiety (exploratory vs. acute threat), making direct comparisons complex.

How to read the evidence

This is a well-designed preclinical study with two complementary experiments: agonist administration followed by antagonist verification. The dual-experiment design strengthens the receptor-specificity conclusions. However, as an animal study with direct brain injection, clinical applicability is limited and findings require validation in human-relevant models.

When this study was published

Published in 2013, this study is over a decade old but remains relevant as foundational work on NPY Y2 receptor function in anxiety. Subsequent research has continued to explore NPY-based anxiolytic strategies informed by studies like this.

The bigger picture

Neuropeptide Y is one of the most abundant peptides in the brain and has been consistently linked to resilience against stress and anxiety. Military research has found that special forces soldiers have higher NPY levels, and low NPY is associated with PTSD vulnerability. This study adds anatomical and receptor-level precision to the NPY-anxiety connection, showing that Y2 receptors in the lateral septum are a key node in this system. Such findings could guide the development of intranasal NPY or Y2-selective peptide agonists as targeted anxiolytics.

Questions still open

Could Y2 receptor-selective peptide agonists be developed as targeted anxiolytic drugs with fewer side effects than current medications?
Do Y2 receptors in the lateral septum also mediate the stress-resilience effects of NPY observed in trauma research?
Why does Y2 activation reduce exploratory anxiety but not immediate threat responses, and what does this mean for treating different anxiety disorders?

Common questions

What is neuropeptide Y and what does it do in the brain?

Neuropeptide Y (NPY) is a 36-amino-acid peptide and one of the most abundant signaling molecules in the brain. It plays roles in appetite regulation, stress response, and anxiety. NPY generally has calming, anti-anxiety effects — people with higher NPY levels tend to be more resilient to stress. It works through several receptor types (Y1 through Y5), each with different functions and locations in the brain. This study focused on the Y2 receptor subtype in a specific brain region involved in processing threat.

Why did the anti-anxiety effect depend on the type of test used?

Different anxiety tests model different real-world situations. The elevated plus-maze measures willingness to explore potentially dangerous open spaces — similar to generalized anxiety about uncertain situations. The shock-probe test measures response to an actual painful stimulus — more like an acute fear reaction. The finding that Y2 receptors in the lateral septum reduce exploratory anxiety but not acute fear suggests that different types of anxiety are regulated by different brain circuits, which is why a single medication often doesn't treat all anxiety symptoms equally.

Read the original research

Lateral septal infusions of the neuropeptide Y Y2 receptor agonist, NPY(13-36) differentially affect different defensive behaviors in male, Long Evans rats.

Physiology & behavior, 110-111, 20-9

View on PubMed ↗Publisher’s paper ↗

Citation

Trent, Natalie L; Menard, Janet L. (2013). Lateral septal infusions of the neuropeptide Y Y2 receptor agonist, NPY(13-36) differentially affect different defensive behaviors in male, Long Evans rats.. Physiology & behavior, 110-111, 20-9. https://doi.org/10.1016/j.physbeh.2012.12.011